Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8N1Q1

UPID:
CAH13_HUMAN

ALTERNATIVE NAMES:
Carbonate dehydratase XIII; Carbonic anhydrase XIII

ALTERNATIVE UPACC:
Q8N1Q1

BACKGROUND:
The enzyme Carbonic anhydrase 13, known alternatively as Carbonate dehydratase XIII, is integral to the reversible hydration of carbon dioxide. This process is essential for the regulation of acid-base balance within organisms, highlighting the enzyme's significance in metabolic pathways. Carbonic anhydrase 13's activity is vital for the conversion of carbon dioxide to bicarbonate, a critical reaction in physiological environments.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Carbonic anhydrase 13 holds promise for identifying new therapeutic avenues. Given its central role in carbon dioxide hydration and acid-base equilibrium, targeting this enzyme could lead to innovative treatments for disorders associated with disrupted pH homeostasis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.